Skip to main content
Menu

Select a tool from the sidebar

Portfolio
common.loading
Sign In Get Started
Carl Zeiss Meditec AG (AFX.DE)
AFX.DE
Carl Zeiss Meditec AG (AFX.DE)
29.0800 €
-0.3800 (%-1.29)
Overview
Technicals
Financial Statements
Comments
Archive

AFX.DE: Carl Zeiss Meditec AG Financials

Income statement, balance sheet, cash flow and financial performance data for Carl Zeiss Meditec AG.

Carl Zeiss Meditec AG Income Statement

Chart
Gross margin TTM
52.76%
Operating margin TTM
10.02%
Net profit margin TTM
6.34%
Return on investment TTM
6.67%
Period end30/09/202530/09/202430/09/202330/09/2022
Total revenue2,227,645,0002,066,127,0002,089,300,0001,902,836,000
Operating income223,320,000194,452,000348,124,000396,879,000
Net income141,210,000178,726,000290,396,000293,909,000

All line items

Line item30/09/202530/09/202430/09/202330/09/2022
Total revenue2,227,645,0002,066,127,0002,089,300,0001,902,836,000
Cost of revenue1,052,448,000977,497,000883,535,000775,238,000
Gross profit1,175,197,0001,088,630,0001,205,765,0001,127,598,000
Research and development expenses326,275,000343,089,000349,278,000291,365,000
General and administrative expenses131,421,000111,010,00083,778,00077,881,000
Selling and marketing expenses495,098,000458,198,000420,279,000360,179,000
Selling, general and administrative expenses626,519,000569,208,000504,057,000438,060,000
Other expenses-917,000-18,119,0004,306,0001,294,000
Operating expenses951,877,000894,178,000857,641,000730,719,000
Cost and expenses2,004,325,0001,871,675,0001,741,176,0001,505,957,000
Net interest income-20,054,00037,852,00012,861,0004,151,000
Interest income6,570,00023,273,00028,111,00013,250,000
Interest expense26,624,000-14,579,00015,250,0009,099,000
Depreciation and amortization126,378,000132,771,00074,063,00069,769,000
EBITDA346,894,000403,061,000501,877,000482,851,000
EBIT220,516,000270,290,000427,814,000413,082,000
Non-operating income (excl. interest)2,804,000-75,838,000-79,690,000-16,203,000
Operating income223,320,000194,452,000348,124,000396,879,000
Total other income/expenses (net)-29,428,00046,414,00064,440,0006,610,000
Income before tax193,892,000240,866,000412,564,000403,489,000
Income tax expense51,547,00060,712,000120,555,000107,578,000
Net income from continuing operations142,345,000180,154,000292,009,000295,911,000
Net income from discontinued operations0000
Other adjustments to net income0000
Net income141,210,000178,726,000290,396,000293,909,000
Net income deductions0000
Bottom line net income141,210,000178,726,000290,396,000293,909,000
EPS2233
Diluted EPS2233
Weighted average shares outstanding87,536,07988,851,08489,440,57089,440,570
Weighted average diluted shares outstanding87,536,07988,851,06189,440,57089,440,570

Carl Zeiss Meditec AG Balance Sheet

Period endTotal assetsTotal liabilities & equity
30/09/20253,459,437,0001,331,738,000
30/09/20243,393,200,0001,336,721,000
30/09/20233,032,924,000860,021,000
30/09/20222,822,817,000792,726,000
Long-term debt / assets MRQ
455,357,000%
Period end30/09/202530/09/202430/09/202330/09/2022
Total assets3,459,437,0003,393,200,0003,032,924,0002,822,817,000
Total liabilities1,331,738,0001,336,721,000860,021,000792,726,000
Total equity2,116,506,0002,041,697,0002,159,453,0002,015,100,000

All line items

Line item30/09/202530/09/202430/09/202330/09/2022
Cash and cash equivalents27,267,00020,285,00010,601,0007,729,000
Short-term investments0000
Cash and short-term investments27,267,00020,285,00010,601,0007,729,000
Net receivables691,684,000583,184,0001,297,152,0001,366,436,000
Accounts receivable209,013,000209,053,000196,916,000197,801,000
Other receivables482,671,000373,882,0001,099,462,0001,168,635,000
Inventory496,982,000536,556,000520,228,000382,745,000
Prepaid expenses2,077,0005,005,0006,588,00014,245,000
Other current assets62,288,00067,453,00077,158,00020,698,000
Total current assets1,280,298,0001,212,483,0001,911,727,0001,791,853,000
Property, plant and equipment (net)342,953,000353,763,000315,773,000236,145,000
Goodwill969,740,000982,505,000415,783,000429,648,000
Intangible assets662,873,000706,850,000259,489,000240,427,000
Goodwill and intangible assets1,632,613,0001,689,355,000675,272,000670,075,000
Long-term investments48,490,00020,378,00021,455,00019,454,000
Tax assets82,261,00086,320,00063,704,00071,749,000
Other non-current assets72,822,00030,901,00044,993,00033,541,000
Total non-current assets2,179,139,0002,180,717,0001,121,197,0001,030,964,000
Other assets0000
Total assets3,459,437,0003,393,200,0003,032,924,0002,822,817,000
Total payables119,097,000280,924,000292,125,000242,574,000
Accounts payable108,927,000183,542,000239,792,000189,185,000
Other payables10,170,00097,382,00052,333,00053,389,000
Accrued expenses0123,636,000095,482,000
Short-term debt43,691,0002,481,00045,998,0000
Capital lease obligations (current)24,138,00024,590,00021,816,00021,587,000
Tax payables28,997,00033,343,00035,597,00023,714,000
Deferred revenue00039,908,000
Other current liabilities356,885,000137,204,000201,707,000139,765,000
Total current liabilities543,811,000568,835,000561,646,000539,316,000
Long-term debt455,357,000458,897,00096,030,00091,179,000
Capital lease obligations (non-current)108,318,000126,757,000133,880,000106,316,000
Deferred revenue (non-current)0000
Deferred tax liabilities (non-current)188,288,000138,482,00035,039,00022,379,000
Other non-current liabilities35,964,00043,750,00033,426,00033,535,999
Total non-current liabilities787,927,000767,886,000298,375,000253,410,000
Other liabilities0000
Capital lease obligations132,456,000151,347,000155,696,000127,903,000
Total liabilities1,331,738,0001,336,721,000860,021,000792,726,000
Treasury stock-150,075,000-150,075,00000
Preferred stock0000
Common stock89,441,00089,441,00089,441,00089,441,000
Retained earnings1,575,111,0001,486,423,0001,405,901,0001,213,890,000
Additional paid-in capital620,137,000620,137,000620,137,000620,137,000
Accumulated other comprehensive income/loss-18,107,999-4,229,00043,974,00091,632,000
Other stockholders' equity0000
Total stockholders' equity2,116,506,0002,041,697,0002,159,453,0002,015,100,000
Total equity2,127,699,0002,056,479,0002,172,903,0002,030,091,000
Minority interest11,193,00014,782,00013,450,00014,991,000
Total liabilities and total equity3,459,437,0003,393,200,0003,032,924,0002,822,817,000
Total investments48,490,00020,378,00021,455,00019,454,000
Total debt607,366,000612,725,000297,724,000219,082,000
Net debt580,099,000592,440,000287,123,000211,353,000

Carl Zeiss Meditec AG Cash Flow Statement

Chart
Period end30/09/202530/09/202430/09/202330/09/2022
Cash from operations209,858,000247,319,000250,861,000188,199,000
Cash from investing-91,027,000-412,305,000-110,980,000-148,894,000
Cash from financing-108,827,000176,249,000-135,094,000-38,236,000
Net change in cash6,982,0009,684,0002,872,000290,000

All line items

Line item30/09/202530/09/202430/09/202330/09/2022
Net income142,345,000178,726,000292,009,000293,909,000
Depreciation and amortization126,378,000132,771,00074,063,00069,769,000
Deferred income tax000-7,334,000
Stock-based compensation0000
Change in working capital-36,666,00015,104,000-125,879,000-109,510,000
Accounts receivable-106,479,00021,616,000-21,178,000-74,370,000
Inventory26,600,00024,377,000-152,604,000-74,631,000
Accounts payable15,268,000-63,298,00047,098,00033,729,000
Other working capital27,945,00032,409,000805,0005,762,000
Other non-cash items-22,199,000-79,282,00010,668,000-58,635,000
Net cash from operating activities209,858,000247,319,000250,861,000188,199,000
Investments in property, plant and equipment-39,394,000-86,814,000-65,651,000-81,971,000
Acquisitions (net)-2,469,000-1,006,279,000-10,664,000-61,290,000
Purchases of investments-25,653,000-3,904,000-21,594,000-5,851,000
Sales/maturities of investments0750,016,00034,784,00056,008,000
Other investing activities-23,511,000-65,324,000-47,855,000-55,790,000
Net cash from investing activities-91,027,000-412,305,000-110,980,000-148,894,000
Net debt issuance68,000400,206,000-8,000-2,053,000
Long-term net debt issuance0400,000,000-22,990,000-21,360,000
Short-term net debt issuance68,000206,000-8,000-597,000
Net stock issuance0-150,075,00000
Net common stock issuance0-150,075,00000
Common stock issuance0000
Common stock repurchased0-150,075,00000
Net preferred stock issuance0000
Net dividends paid-52,522,000-98,204,000-98,385,000-80,497,000
Common dividends paid-52,522,000-98,204,000-98,385,000-80,497,000
Preferred dividends paid0000
Other financing activities-56,373,00024,322,000-36,701,00044,314,000
Net cash from financing activities-108,827,000176,249,000-135,094,000-38,236,000
Effect of FX changes on cash-3,022,000-1,579,000-1,915,000-779,000
Net change in cash6,982,0009,684,0002,872,000290,000
Cash at end of period27,267,00020,285,00010,601,0007,729,000
Cash at beginning of period20,285,00010,601,0007,729,0007,439,000
Operating cash flow209,858,000247,319,000250,861,000188,199,000
Capital expenditure-39,394,000-152,204,000-113,861,000-81,971,000
Free cash flow170,464,00095,115,000137,000,000106,228,000
Income taxes paid0000
Interest paid0000